Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Blood advances·2026
Same author

Coincidence or Connection? Revisiting the Relationship Between Mastocytosis and Lymphoma.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC.

Journal of cellular and molecular medicine·2026
Same author

Clonal Dynamics of FLT3-ITD from Diagnosis to Relapse: Ultra-Sensitive Patient-Specific Monitoring by ddPCR.

International journal of molecular sciences·2026
Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026
Same author

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Blood advances·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

CML: a model for targeted therapy.

Daniela Cilloni1, Giuseppe Saglio

  • 1Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Best Practice & Research. Clinical Haematology
|December 5, 2009
PubMed
Summary
This summary is machine-generated.

The Philadelphia chromosome discovery advanced understanding of blood cancers. While BCR-ABL is a key target in chronic myeloid leukemia (CML), its exact role in initiating the disease and the genomic instability involved remain unclear.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Related Experiment Videos

Last Updated: Jun 18, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The Philadelphia (Ph) chromosome discovery was pivotal in understanding hematological malignancies.
  • Characterization of the t(9;22)(q34;q11) translocation and BCR-ABL gene confirmed its central role in chronic myeloid leukemia (CML).
  • BCR-ABL has become a crucial therapeutic target in CML treatment.

Purpose of the Study:

  • To investigate the initiating role of the BCR-ABL fusion gene in the chronic phase of CML.
  • To explore the underlying genomic instability contributing to BCR-ABL fusion gene production.
  • To understand how Ph-positive clones acquire further genetic events leading to advanced disease phases.

Main Methods:

  • Review of historical discoveries and experimental evidence linking BCR-ABL to CML.
  • Analysis of molecular mechanisms underlying chromosomal translocations in leukemia.
  • Examination of genetic events and clonal evolution in chronic myeloid leukemia.

Main Results:

  • The central role of BCR-ABL in CML is well-established, leading to its use as a therapeutic target.
  • Uncertainty remains regarding BCR-ABL as the sole initiating lesion for CML's chronic phase.
  • Incomplete understanding of genomic instability's role in fusion gene formation and disease progression.

Conclusions:

  • While BCR-ABL is a validated therapeutic target, its precise initiating role in CML requires further investigation.
  • Genomic instability is a critical factor in the development of CML and disease advancement.
  • Further research is needed to fully elucidate the molecular pathogenesis of CML and its progression.